Robert Califf’s confirmation as FDA commissioner clears Senate HELP Committee

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Senate Health, Education, Labor, and Pension Committee voted 13-8 to confirm Robert Califf as the next commissioner of FDA. 

Next, Califf’s candidacy goes to the full Senate.

Table of Contents

YOU MAY BE INTERESTED IN

FDA issued a Complete Response Letter to Summit Therapeutics Inc. regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody.
FDA approved Wilserdly (giredestrant) in combination with everolimus for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.
FDA approved Imfinzi (durvalumab)​ in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. 
FDA granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login